Quantum & MedTech Frontier

Horizon Therapeutics updated UPLIZNA prescribing information on September 29, 2026, outlining its use as a CD19-directed cytolytic antibody for...

Three nAMD gene therapies near pivotal data that will determine if one-time treatment can replace or sharply reduce repeated anti-VEGF injections....

A single-dose gene therapy in dogs with CaBP4 mutations not only halted vision loss but physically repaired damaged retinal connections, expanding the...

Verismo's upcoming SITC 2026 poster highlights mesothelin-targeted multi-chain KIR-CAR T cells reducing exhaustion and cytokine release versus CD28 or...

CSL's $355 million upfront and up to $1.6 billion total commitment to co-develop Alentis' Phase 2 lixudebart signals how big-pharma partnerships...

A clear trend is emerging: biopharma companies are rapidly expanding specialized manufacturing to support complex therapies and commercial supply.

-...

More than 1,300 AI devices have reached U.S. hospitals via FDA clearance, yet only three have been tested for whether patients live longer or feel...

The FDA granted Retatrutide Breakthrough Therapy designation for obesity, acknowledging preliminary clinical evidence. This milestone signals progress but leaves open when the drug will reach approved, affordable real-world use.

FDA advisory endorsement pushed Grail shares up 11% as its Galleri test nears final approval for detecting 50 cancers from one blood draw. Yet the...

Psychedelics edge toward commercialization as COMP360 psilocybin advances a rolling FDA application after two Phase 3 wins in treatment-resistant...

D-Wave's new collaboration with the University of Arkansas Walton College establishes a Quantum Supply Chain Initiative to apply annealing and...

Palvella completed its NDA for QTORIN rapamycin in August and secured a third year of FDA orphan-product grant funding for the Phase 3 SELVA trial,...

• Current price near lows: XNDU trades at ~4.5, close to its 52-week floor of 4.28 after peaking at 42.44, showing sharp pullback.
• High trading...

Roivant’s Lisraya launch tests whether the company can graduate from asset-hunting to sustained commercialization, after its earlier Vtama rollout...

Rusfertide's FDA approval marks a shift away from repeated phlebotomy for polycythemia vera patients reliant on it to control hematocrit.

-...

Quantum infrastructure is shifting from labs to real deployments, with customer orders and hybrid on-prem setups signaling early commercial...

Can tavapadon, a selective D1/D5 agonist, serve as a meaningful first-line option or levodopa complement in newly diagnosed patients?

• TEMPO-2...

Can VYD2311’s safety profile support accelerated approval for antibody-based prevention?

• Clear safety advantage: Phase III LIBERTY showed...

Workflow automation may determine how fast CRISPR moves from lab edits to reproducible industrial use.

• DropGenie’s device cuts required cells...

John Martinis, Nobel laureate and Qolab co-founder, stresses that million-qubit superconducting systems are limited by manufacturing and integration,...